

C2  
cont.  
D-mannitol, glucose and glycerin. Example of the pH-modifier include, but are not limited to, phosphates such as monosodium phosphate and sodium hydrogenphosphate, sodium hydroxide and hydrochloric acid. Examples of the antioxidant include, but are not limited to, vitamin C.

IN THE CLAIMS

Please cancel claims 1-10, 12, 13, 16 and 18 without prejudice or disclaimer.

Please amend claim 11 as follows:

D1  
C3  
11. (Amended) A method for inhibitory ocular Langerhans cell migration in a mammal comprising administering an effective amount of a Langerhans cell migration inhibitor comprising a compound selected from dihydroxy vitamin D<sub>3</sub>; α-calcidol; calcifedol; 1α, 25,26-trihydroxy vitamin D<sub>3</sub>; 1β,25-dihydroxy vitamin D<sub>3</sub>; 24-homo-1α,25-dihydroxy vitamin D<sub>3</sub>; 22-oxacalcitriol; and calcipotriol as an active ingredient to the mammal.

Please amend claim 14 as follows:

C4  
Sub 1  
cont.  
14. (Amended) The method of Claim 11 wherein the compound is calcitriol or 22-oxacalcitriol.

Not further limiting the claim.

Please amend claim 17 as follows:

C.5  
Sub E2  
17. (Amended) The method of Claim 15  
wherein the Langerhans cell migration causes  
keratoconjunctivitis.

Please amend claim 19 as follows:

Sub E3  
C.6  
19. (Amended) The method of Claim 15  
wherein the Langerhans cell migration causes phlyctenular  
keratitis or corneal infiltration.

Please amend claim 20 as follows:

C.7  
Sub E3  
Contd  
20. (Amended) The method of Claim 15 wherein  
the inhibitor prevents and/or treats an ocular  
inflammation by inhibiting the production of  
interleukin-1 in corneal epithelial  
cells caused by Langerhans cell migration.